Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors

  1. Ramachandran S. Vasan, MD;
  2. Lisa M. Sullivan, PhD;
  3. Peter W.F. Wilson, MD;
  4. Christopher T. Sempos, PhD;
  5. Johan Sundström, MD, PhD;
  6. William B. Kannel, MD;
  7. Daniel Levy, MD; and
  8. Ralph B. D'Agostino, PhD
  1. From the Framingham Heart Study, Framingham, Massachusetts; Medical University of South Carolina, Charleston, South Carolina; State University of New York at Buffalo, Buffalo, New York; National Heart, Lung, and Blood Institute, Bethesda, Maryland; and Boston University, Boston, Massachusetts.

    Abstract

    Background: Clinical trials indicate that a sizable proportion of adults have multiple borderline coronary risk factors and may benefit from treatment.

    Objective: To estimate the relative and absolute contributions of borderline and elevated risk factors to the population burden of coronary heart disease (CHD) events.

    Design: A prospective cohort study and a national cross-sectional survey.

    Setting: The Framingham Study and the Third National Health and Nutrition Examination Survey (NHANES III).

    Participants: White non-Hispanic persons in the Framingham Study and in NHANES III who were between 35 to 74 years of age and had no CHD.

    Measurements: Occurrence of first CHD events according to 5 major CHD risk factors: blood pressure, low-density lipoprotein and high-density lipoprotein cholesterol levels, glucose intolerance, and smoking. Three categories—optimal, borderline, and elevated—were defined for each risk factor per national guidelines. Sex-specific 10-year CHD event rates from the Framingham Study were applied to numbers of at-risk individuals estimated from NHANES III and the 2000 U.S. Census.

    Results: Twenty-six percent of men and 41% of women had at least 1 borderline risk factor in NHANES III. According to estimates, more than 90% of CHD events will occur in individuals with at least 1 elevated risk factor, and approximately 8% will occur in people with only borderline levels of multiple risk factors. Absolute 10-year CHD risk exceeded 10% in men older than age 45 years who had 1 elevated risk factor and 4 or more borderline risk factors and in those who had at least 2 elevated risk factors. In women, absolute CHD risk exceeded 10% only in those older than age 55 years who had at least 3 elevated risk factors.

    Limitations: The generalizability of the findings to persons of other ethnic backgrounds is unknown.

    Conclusions: Borderline CHD risk factors alone account for a small proportion of CHD events.

    Article and Author Information

    • Potential Financial Conflicts of Interest: None disclosed.

    • Requests for Single Reprints: Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803; e-mail, vasan{at}bu.edu.

    • Current Author Addresses: Drs. Vasan, Kannel, and Levy: Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803.

    • Drs. Sullivan and D'Agostino: Boston University Statistics and Consulting Unit, 704 Commonwealth Avenue, 5th Floor, Boston, MA 02215.

    • Dr. Wilson: Department of Endocrinology, Diabetes, and Medical Genetics, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 215, Charleston, SC 29425.

    • Dr. Sempos: Department of Social & Preventive Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214.

    • Dr. Sundström: Department of Public Health & Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.

    • Author Contributions: Conception and design: R.S. Vasan, L.M. Sullivan, P.W.F. Wilson, J. Sundström, W.B. Kannel, D. Levy, R.B. D'Agostino.

    • Analysis and interpretation of the data: R.S. Vasan, L.M. Sullivan, P.W.F. Wilson, C.T. Sempos, J. Sundström, W.B. Kannel, D. Levy, R.B. D'Agostino.

    • Drafting of the article: R.S. Vasan, L.M. Sullivan, J. Sundström, W.B. Kannel, D. Levy, R.B. D'Agostino.

    • Critical revision of the article for important intellectual content: R.S. Vasan, P.W.F. Wilson, C.T. Sempos, J. Sundström, W.B. Kannel, D. Levy.

    • Final approval of the article: R.S. Vasan, L.M. Sullivan, P.W.F. Wilson, C.T. Sempos, J. Sundström, W.B. Kannel, D. Levy, R.B. D'Agostino.

    • Provision of study materials or patients: P.W.F. Wilson, D. Levy, R.B. D'Agostino.

    • Statistical expertise: L.M. Sullivan, R.B. D'Agostino.

    • Obtaining of funding: R.S. Vasan, R.B. D'Agostino.

    • Administrative, technical, or logistic support: P.W.F. Wilson, D. Levy, R.B. D'Agostino.

    • Collection and assembly of data: P.W.F. Wilson, D. Levy, R.B. D'Agostino.

    Comments on This Article

    Related Article

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement